



OROX BioSciences is a biotechnology start-up company dedicated to efficient discovery and development of innovative small molecule drugs to address unmet medical needs for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) as well as oncology. Our core technology is around inhibition of soluble epoxide hydrolase (sEH) to ameliorate disease states. The core competence of our team is understanding lipid metabolism and its interphase with disease states.



Mehran Moghaddam, PhD
CEO | OROX BioSciences, Inc.
memo@oroxbios.com



AZZUR GROUP

Azzur Group partners with leading pharmaceutical, biotechnology, and medical device manufacturers to provide efficient and innovative solutions that help them start, scale, and sustain their GxP organizations. With experts at more than 15 locations throughout the United States, we take pride in our development and execution of phase-appropriate quality and compliance services to our clients From Discovery To Delivery™.




<https://azzur.com/>

Ming Wang

Director, Consulting Services | Azzur Group

ming.wang@azzur.com



ImpriMed, a team of doctors from Stanford University, develops a personalized drug test kit to help doctors treat cancer patients with precision medicine, based on drug-cell interaction data of individual patient's sample. Doctors choose candidate drugs they want to test, and we provide a customized drug array to clinics that enables doctors to pre-test a number of cancer drug combinations using patient's biopsy samples before finalizing which drugs to inject into the patient body.



<https://www.imprimedicine.com/>

Jamin Koo, PhD
Co-founding director | ImpriMed, Inc
jamin@imprimedicine.com

VENABLE LLP



"Venable LLP is a firm of trusted advisors serving businesses, organizations, and individuals in many of the most important aspects of their work.

Our professionals immerse themselves in our clients' work to fully understand their biggest opportunities and challenges while helping them navigate an increasingly complex legal and regulatory environment. Today, with more than 850 professionals delivering services around the world, we're helping our clients connect quickly and effectively to the experience, insights, and advice to achieve their most pressing objectives.

Cultivated over more than 120 years, Venable's capabilities span virtually every industry and all areas of regulatory and government affairs, corporate and business law, intellectual property, and complex litigation. Many of our professionals are former regulators, senior government staffers, state attorneys general, and members of Congress—bringing an invaluable depth of experience to our firm. At the same time, we foster a diverse culture that helps ensure our ability to attract, retain, and elevate the most talented professionals in the country, who work on behalf of our clients."

<https://www.venable.com>



Prajakta Sonalker, PhD

Partner, Life Sciences IP | Venable LLP

pasonalker@venable.com



Yeon Jae Ko, PhD

Attorney | Venable LLP

yko@venable.com


 ADVANCED
TARGETING
SYSTEMS

California • Netherlands • Distributors Worldwide

ATSBio.com

Advanced Targeting Systems (ATS) is a San Diego-based biotechnology company dedicated to providing quality targeting reagents for scientific research and pharmaceutical development worldwide. Since 1994, ATS has focused on the development of products for the Neuroscience research community. The Company's current product line includes targeted toxins, antibodies and custom conjugation services designed to assist scientists in the study of nervous system function, brain-related diseases and disorders. The technology that provides the foundation for the Company's products has a broad spectrum of applications, not only in the field of Neuroscience, but in virtually every medical and pharmaceutical research field. ATS is continuing to develop and expand the existing product line through strategic scientific collaborations with top scientists throughout the world.

<https://atsbio.com/>



Jung-Hee Woo, PhD
Chief Manufacturing Officer | Advanced
Targeting Systems
junghee@atsbio.com



Transforming the engineering of cell-based therapies

"We are Basilard BioTech.

We have introduced our novel gene delivery technology platform, Celletto™ to transform the rapidly growing cell-based therapies market. Celletto™ is a differentiated & superior solution for non-viral gene delivery.

Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies.

This is the bottleneck Celletto™ addresses with our new, disruptive, IP-Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. In ex-vivo delivery, Celletto™ consistently achieves higher transfection and cell viability performance and yields vs. the industry leading bulk electroporation platform currently used widely. In viral delivery, Celletto™ provides greater scalability, safety, efficiency, & versatility than prevailing viral delivery methods, as well as lower cost & lead time. And Celletto™ is a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods."



Brynley Lee

CEO | Basilard BioTech

brynleylee@basilardbiotech.net

<https://basilardbiotech.com/>




"Helico's goal is to unlock the innate ability of plants to become factories for medicinal compounds.

Employing innovative research in computational biology and plant molecular biology, we design plant models able to produce therapeutic compounds.

Our mission is to bring medicines where they are needed the most, using local and eco-friendlier pharmaceutical production systems."

<https://www.helico.bio/>



Ilya Vensky
CoFounder & CEO | Helico Bio
ilya@helico.bio

UC San Diego

"Improving health and quality of life by applying engineering principles to scientific discovery and technology innovation, and training diverse future leaders in Bioengineering through inspiring education and dedicated mentorship.

Bioengineering, one of the youngest engineering disciplines, employs the principles and tools of engineering to analyze and solve biological and medical problems. It is broad in its spectrum, with its foundation in all of the traditional engineering sciences, as well as biology, physiology and other biomedical sciences. UC San Diego is at the forefront of bioengineering.

The Department of Bioengineering ranks 5th in the nation for biomedical/ bioengineering (US News and World Report Ranking of Best Engineering Schools, published April 2023). We broadly categorize our research interests to embrace three pillars of bioengineering: multiscale bioengineering, tissue engineering and regenerative medicine, and systems biology and medicine. With established and promising up-and-coming core faculty, our department has four disease focus areas including cancer, cardiovascular diseases, metabolic disorders, and neurodegenerative diseases."

<https://be.ucsd.edu/>



Jung Joo Hwang, PhD
Director of i3 | UCSD Department
of Bioengineering
j4hwang@ucsd.edu

RX PROPELLANT

Building for Breakthroughs

Rx Propellant is a Lifesciences infrastructure platform propelling the growth of world-class clusters to facilitate science and innovation. The Rx Propellant platform is a part of portfolio of Actis, a leading global investor in sustainable infrastructure, headquartered in London, UK. We develop state-of-the-art labspaces and flexi factories to enable R&D and manufacturing operations across Lifesciences value chains. Our vision is to create cohesive ecosystems encompassing real estate, start-ups incubation, scientific networking, and talent nurturing.

<https://rxpropellant.com/>



Managing Director | Rx Propellant
vishal.goel@rxpropellant.com



Vice President, International BD &
Strategy | Rx Propellant
ketki.tulpule@rxpropellant.com